Summary of Study ST002835
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001775. The data can be accessed directly via it's Project DOI: http://dx.doi.org/10.21228/M88M6V This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002835 |
Study Title | Investigation of FGFR signaling controlled metabolism in FGFR2-fusion+ intrahepatic cholangiocarcinoma |
Study Summary | Genomic alterations that activate FGFR2 are common in intrahepatic cholangiocarcinoma (ICC) and confer sensitivity to treatment with FGFR inhibitors. However, the depth and duration of responses are often limited. Elucidating the FGFR2-driven oncogenic program and the adaptions to FGFR inhibition is needed to gain insight into the biology of these tumors and inform future therapeutic development. Here, we conducted metabolomic analysis of patient-derived models to define the pathways that fuel tumor growth downstream of oncogenic FGFR2 signaling in ICC and to uncover compensatory mechanisms associated with pathway inhibition. We find FGFR2-fusion+ ICC maintains a highly glycolytic phenotype in FGFR2+ ICC. Conversely, FGFR inhibition blocks glucose uptake and glycolysis, while inciting a series of adaptive changes. Thus, we show that glycolysis is a key downstream effector of oncogenic FGFR2 signaling in ICC, and that pronounced metabolic reprogramming in response to FGFR inhibition confers new targetable vulnerabilities. |
Institute | Massachusetts General Hospital |
Last Name | Zhen |
First Name | Yuanli |
Address | 185 cambridge street, room 4100 |
yzhen1@mgh.harvard.edu | |
Phone | 4698792279 |
Submit Date | 2023-08-26 |
Raw Data Available | Yes |
Raw Data File Type(s) | mzML |
Analysis Type Detail | LC-MS |
Release Date | 2024-03-20 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Factors:
Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)
mb_sample_id | local_sample_id | cell line | treatment | labeling status |
---|---|---|---|---|
SA307239 | SUB11589p2_Spl09 | ICC13-7 | control | 13C6-Glucose Isotopic tracing 0h as ctrl |
SA307240 | SUB11589p2_Spl07 | ICC13-7 | control | 13C6-Glucose Isotopic tracing 0h as ctrl |
SA307241 | SUB11589p2_Spl08 | ICC13-7 | control | 13C6-Glucose Isotopic tracing 0h as ctrl |
SA307242 | SUB11589p2_Spl15 | ICC13-7 | control | 13C6-Glucose Isotopic tracing 1h |
SA307243 | SUB11589p2_Spl14 | ICC13-7 | control | 13C6-Glucose Isotopic tracing 1h |
SA307244 | SUB11589p2_Spl16 | ICC13-7 | control | 13C6-Glucose Isotopic tracing 1h |
SA307245 | SUB11589p2_Spl20 | ICC13-7 | control | 13C6-Glucose Isotopic tracing 24h |
SA307246 | SUB11589p2_Spl21 | ICC13-7 | control | 13C6-Glucose Isotopic tracing 24h |
SA307247 | SUB11589p2_Spl22 | ICC13-7 | control | 13C6-Glucose Isotopic tracing 24h |
SA307230 | SUB11589p2_Spl12 | ICC13-7 | Infigratinib | 13C6-Glucose Isotopic tracing 0h as ctrl |
SA307231 | SUB11589p2_Spl10 | ICC13-7 | Infigratinib | 13C6-Glucose Isotopic tracing 0h as ctrl |
SA307232 | SUB11589p2_Spl11 | ICC13-7 | Infigratinib | 13C6-Glucose Isotopic tracing 0h as ctrl |
SA307233 | SUB11589p2_Spl17 | ICC13-7 | Infigratinib | 13C6-Glucose Isotopic tracing 1h |
SA307234 | SUB11589p2_Spl18 | ICC13-7 | Infigratinib | 13C6-Glucose Isotopic tracing 1h |
SA307235 | SUB11589p2_Spl19 | ICC13-7 | Infigratinib | 13C6-Glucose Isotopic tracing 1h |
SA307236 | SUB11589p2_Spl24 | ICC13-7 | Infigratinib | 13C6-Glucose Isotopic tracing 24h |
SA307237 | SUB11589p2_Spl25 | ICC13-7 | Infigratinib | 13C6-Glucose Isotopic tracing 24h |
SA307238 | SUB11589p2_Spl23 | ICC13-7 | Infigratinib | 13C6-Glucose Isotopic tracing 24h |
SA307248 | SUB11589p2_Spl32 | ICC21 | Afatinib | N/A |
SA307249 | SUB11589p2_Spl33 | ICC21 | Afatinib | N/A |
SA307250 | SUB11589p2_Spl34 | ICC21 | Afatinib | N/A |
SA307251 | SUB11589p2_Spl36 | ICC21 | Combo | N/A |
SA307252 | SUB11589p2_Spl37 | ICC21 | Combo | N/A |
SA307253 | SUB11589p2_Spl35 | ICC21 | Combo | N/A |
SA307257 | SUB11589p2_Spl28 | ICC21 | control | N/A |
SA307258 | SUB11589p2_Spl26 | ICC21 | control | N/A |
SA307259 | SUB11589p2_Spl27 | ICC21 | control | N/A |
SA307254 | SUB11589p2_Spl29 | ICC21 | Infigratinib | N/A |
SA307255 | SUB11589p2_Spl30 | ICC21 | Infigratinib | N/A |
SA307256 | SUB11589p2_Spl31 | ICC21 | Infigratinib | N/A |
Showing results 1 to 30 of 30 |